目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Disease
1.2.2. Treatment
1.2.3. Route of Administration
1.2.4. End Use
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives

Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Acute Myeloid Leukemia Treatment Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.4. Pipeline Analysis

Chapter 4. Acute Myeloid Leukemia Treatment Market: Disease Business Analysis
4.1. Disease Market Share, 2024 & 2030
4.2. Disease Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
4.4. Myeloblastic Leukemia
4.4.1. Myeloblastic Leukemia Market, 2018 - 2030 (USD Million)
4.5. Myelomonocytic Leukemia
4.5.1. Myelomonocytic Leukemia Market, 2018 - 2030 (USD Million)
4.6. Promyelocytic Leukemia
4.6.1. Promyelocytic Leukemia Market, 2018 - 2030 (USD Million)
4.7. Monocytic Leukemia
4.7.1. Monocytic Leukemia Market, 2018 - 2030 (USD Million)
4.8. Other Diseases
4.8.1. Other Diseases Market, 2018 - 2030 (USD Million)

Chapter 5. Acute Myeloid Leukemia Treatment Market: Treatment Business Analysis
5.1. Treatment Market Share, 2024 & 2030
5.2. Treatment Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
5.4. Chemotherapy
5.4.1. Chemotherapy Market, 2018 - 2030 (USD Million)
5.4.2. Anti-metabolites
5.4.3. Anti-metabolites Market, 2018 - 2030 (USD Million)
5.4.4. Alkylating Agents
5.4.5. Alkylating Agents Market, 2018 - 2030 (USD Million)
5.4.6. Anthracycline Drugs
5.4.7. Anthracycline Drugs Market, 2018 - 2030 (USD Million)
5.4.8. Others
5.4.9. Others Market, 2018 - 2030 (USD Million)
5.5. Targeted Therapy
5.5.1. Targeted Therapy Market, 2018 - 2030 (USD Million)
5.5.2. FLT3 Inhibitors
5.5.3. FLT3 Inhibitors Market, 2018 - 2030 (USD Million)
5.5.3.1. Rydapt
5.5.3.1.1. Rydapt Market, 2018 - 2030 (USD Million)
5.5.3.2. Vanflyta
5.5.3.2.1. Vanflyta Market, 2018 - 2030 (USD Million)
5.5.3.3. Xospata
5.5.3.3.1. Xospata Market, 2018 - 2030 (USD Million)
5.5.4. IDH Inhibitors
5.5.5. IDH Inhibitors Market, 2018 - 2030 (USD Million)
5.5.5.1. Tibsovo
5.5.5.1.1. Tibsovo Market, 2018 - 2030 (USD Million)
5.5.5.2. Rezlidhia
5.5.5.2.1. Rezlidhia Market, 2018 - 2030 (USD Million)
5.5.5.3. Idhifa
5.5.5.3.1. Idhifa Market, 2018 - 2030 (USD Million)
5.5.6. Mylotarg
5.5.6.1. Mylotarg Market, 2018 - 2030 (USD Million)
5.5.7. BCL-2 Inhibitor
5.5.7.1. BCL-2 Inhibitor Market, 2018 - 2030 (USD Million)
5.5.8. Hedgehog Pathway Inhibitor
5.5.8.1. Hedgehog Pathway Inhibitor Market, 2018 - 2030 (USD Million)
5.6. Immunotherapy
5.6.1. Immunotherapy Market, 2018 - 2030 (USD Million)
5.6.2. Bispecific Antibodies
5.6.2.1. Bispecific Antibodies Market, 2018 - 2030 (USD Million)
5.6.3. Antibody-drug Conjugates
5.6.3.1. Antibody-drug Conjugates Market, 2018 - 2030 (USD Million)
5.6.4. Immune Checkpoint Inhibitors
5.6.4.1. Immune Checkpoint Inhibitors Market, 2018 - 2030 (USD Million)
5.6.5. Chimeric Antigen Receptor (CAR) T-cell Therapy
5.6.5.1. Chimeric Antigen Receptor (CAR) T-cell Therapy Market, 2018 - 2030 (USD Million)
5.7. Other Treatments
5.7.1. Other Treatments Market, 2018 - 2030 (USD Million)

Chapter 6. Acute Myeloid Leukemia Treatment Market: Route of Administration Business Analysis
6.1. Route of Administration Market Share, 2024 & 2030
6.2. Route of Administration Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
6.4. Parenteral
6.4.1. Parenteral Market, 2018 - 2030 (USD Million)
6.5. Oral
6.5.1. Oral Market, 2018 - 2030 (USD Million)

Chapter 7. Acute Myeloid Leukemia Treatment Market: End Use Business Analysis
7.1. End Use Market Share, 2024 & 2030
7.2. End Use Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
7.4. Hospitals and Clinics
7.4.1. Hospitals and Clinics Market, 2018 - 2030 (USD Million)
7.5. Specialty Centers
7.5.1. Specialty Centers Market, 2018 - 2030 (USD Million)
7.6. Homecare Setting
7.6.1. Homecare Setting Market, 2018 - 2030 (USD Million)
7.7. Ambulatory Care Centers
7.7.1. Ambulatory Care Centers Market, 2018 - 2030 (USD Million)

Chapter 8. Acute Myeloid Leukemia Treatment Market: Regional Estimates & Trend Analysis
8.1. Regional Market Share Analysis, 2024 & 2030
8.2. Regional Market Dashboard
8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
8.4. North America
8.4.1. North America Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
8.4.2. U.S.
8.4.2.1. Key Country Dynamics
8.4.2.2. Regulatory Framework
8.4.2.3. Competitive Insights
8.4.2.4. U.S. Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.4.3. Canada
8.4.3.1. Key Country Dynamics
8.4.3.2. Regulatory Framework
8.4.3.3. Competitive Insights
8.4.3.4. Canada Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.4.4. Mexico
8.4.4.1. Key Country Dynamics
8.4.4.2. Regulatory Framework
8.4.4.3. Competitive Insights
8.4.4.4. Mexico Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5. Europe
8.5.1. Europe Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
8.5.2. UK
8.5.2.1. Key Country Dynamics
8.5.2.2. Regulatory Framework
8.5.2.3. Competitive Insights
8.5.2.4. UK Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.3. Germany
8.5.3.1. Key Country Dynamics
8.5.3.2. Regulatory Framework
8.5.3.3. Competitive Insights
8.5.3.4. Germany Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.4. France
8.5.4.1. Key Country Dynamics
8.5.4.2. Regulatory Framework
8.5.4.3. Competitive Insights
8.5.4.4. France Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.5. Italy
8.5.5.1. Key Country Dynamics
8.5.5.2. Regulatory Framework
8.5.5.3. Competitive Insights
8.5.5.4. Italy Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.6. Spain
8.5.6.1. Key Country Dynamics
8.5.6.2. Regulatory Framework
8.5.6.3. Competitive Insights
8.5.6.4. Spain Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.7. Norway
8.5.7.1. Key Country Dynamics
8.5.7.2. Regulatory Framework
8.5.7.3. Competitive Insights
8.5.7.4. Norway Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.8. Denmark
8.5.8.1. Key Country Dynamics
8.5.8.2. Regulatory Framework
8.5.8.3. Competitive Insights
8.5.8.4. Denmark Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.9. Sweden
8.5.9.1. Key Country Dynamics
8.5.9.2. Regulatory Framework
8.5.9.3. Competitive Insights
8.5.9.4. Sweden Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6. Asia Pacific
8.6.1. Asia Pacific Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
8.6.2. Japan
8.6.2.1. Key Country Dynamics
8.6.2.2. Regulatory Framework
8.6.2.3. Competitive Insights
8.6.2.4. Japan Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6.3. China
8.6.3.1. Key Country Dynamics
8.6.3.2. Regulatory Framework
8.6.3.3. Competitive Insights
8.6.3.4. China Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6.4. India
8.6.4.1. Key Country Dynamics
8.6.4.2. Regulatory Framework
8.6.4.3. Competitive Insights
8.6.4.4. India Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6.5. South Korea
8.6.5.1. Key Country Dynamics
8.6.5.2. Regulatory Framework
8.6.5.3. Competitive Insights
8.6.5.4. South Korea Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6.6. Australia
8.6.6.1. Key Country Dynamics
8.6.6.2. Regulatory Framework
8.6.6.3. Competitive Insights
8.6.6.4. Australia Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6.7. Thailand
8.6.7.1. Key Country Dynamics
8.6.7.2. Regulatory Framework
8.6.7.3. Competitive Insights
8.6.7.4. Thailand Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.7. Latin America
8.7.1. Latin America Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
8.7.2. Brazil
8.7.2.1. Key Country Dynamics
8.7.2.2. Regulatory Framework
8.7.2.3. Competitive Insights
8.7.2.4. Brazil Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.7.3. Argentina
8.7.3.1. Key Country Dynamics
8.7.3.2. Regulatory Framework
8.7.3.3. Competitive Insights
8.7.3.4. Argentina Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.8. MEA
8.8.1. MEA Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
8.8.2. South Africa
8.8.2.1. Key Country Dynamics
8.8.2.2. Regulatory Framework
8.8.2.3. Competitive Insights
8.8.2.4. South Africa Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.8.3. Saudi Arabia
8.8.3.1. Key Country Dynamics
8.8.3.2. Regulatory Framework
8.8.3.3. Competitive Insights
8.8.3.4. Saudi Arabia Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.8.4. UAE
8.8.4.1. Key Country Dynamics
8.8.4.2. Regulatory Framework
8.8.4.3. Competitive Insights
8.8.4.4. UAE Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.8.5. Kuwait
8.8.5.1. Key Country Dynamics
8.8.5.2. Regulatory Framework
8.8.5.3. Competitive Insights
8.8.5.4. Kuwait Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape
9.1. Participant Overview
9.2. Company Market Position Analysis
9.3. Company Categorization
9.4. Strategy Mapping
9.5. Company Profiles/Listing
9.5.1. Astellas Pharma Inc.
9.5.1.1. Overview
9.5.1.2. Financial Performance
9.5.1.3. Product Benchmarking
9.5.1.4. Strategic Initiatives
9.5.2. Bristol-Myers Squibb Company
9.5.2.1. Overview
9.5.2.2. Financial Performance
9.5.2.3. Product Benchmarking
9.5.2.4. Strategic Initiatives
9.5.3. DAIICHI SANKYO COMPANY, LIMITED
9.5.3.1. Overview
9.5.3.2. Financial Performance
9.5.3.3. Product Benchmarking
9.5.3.4. Strategic Initiatives
9.5.4. Jazz Pharmaceuticals plc
9.5.4.1. Overview
9.5.4.2. Financial Performance
9.5.4.3. Product Benchmarking
9.5.4.4. Strategic Initiatives
9.5.5. Novartis AG
9.5.5.1. Overview
9.5.5.2. Financial Performance
9.5.5.3. Product Benchmarking
9.5.5.4. Strategic Initiatives
9.5.6. Otsuka Pharmaceuticals Co.,Ltd.
9.5.6.1. Overview
9.5.6.2. Financial Performance
9.5.6.3. Product Benchmarking
9.5.6.4. Strategic Initiatives
9.5.7. Pfizer Inc.
9.5.7.1. Overview
9.5.7.2. Financial Performance
9.5.7.3. Product Benchmarking
9.5.7.4. Strategic Initiatives
9.5.8. Rigel Pharmaceuticals, Inc.
9.5.8.1. Overview
9.5.8.2. Financial Performance
9.5.8.3. Product Benchmarking
9.5.8.4. Strategic Initiatives
9.5.9. Merck KGaA
9.5.9.1. Overview
9.5.9.2. Financial Performance
9.5.9.3. Product Benchmarking
9.5.9.4. Strategic Initiatives
9.5.10. Sanofi
9.5.10.1. Overview
9.5.10.2. Financial Performance
9.5.10.3. Product Benchmarking
9.5.10.4. Strategic Initiatives

List of Tables
Table 1. List of secondary sources
Table 2. List of abbreviations
Table 3. Global acute myeloid leukemia treatment market, by region, 2018 - 2030 (USD Million)
Table 4. Global acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 5. Global acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 6. Global acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 7. Global acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 8. North America acute myeloid leukemia treatment market, by country, 2018 - 2030 (USD Million)
Table 9. North America acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 10. North America acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 11. North America acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 12. North America acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 13. U.S. acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 14. U.S. acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 15. U.S. acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 16. U.S. acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 17. Canada acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 18. Canada acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 19. Canada acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 20. Canada acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 21. Mexico acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 22. Mexico acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 23. Mexico acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 24. Mexico acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 25. Europe acute myeloid leukemia treatment market, by country, 2018 - 2030 (USD Million)
Table 26. Europe acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 27. Europe acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 28. Europe acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 29. Europe acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 30. UK acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 31. UK acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 32. UK acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 33. UK acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 34. Germany acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 35. Germany acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 36. Germany acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 37. Germany acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 38. France acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 39. France acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 40. France acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 41. France acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 42. Italy acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 43. Italy acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 44. Italy acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 45. Italy acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 46. Spain acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 47. Spain acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 48. Spain acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 49. Spain acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 50. Denmark acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 51. Denmark acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 52. Denmark acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 53. Denmark acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 54. Sweden acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 55. Sweden acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 56. Sweden acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 57. Sweden acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 58. Norway acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 59. Norway acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 60. Norway acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 61. Norway acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 62. Asia Pacific acute myeloid leukemia treatment market, by country, 2018 - 2030 (USD Million)
Table 63. Asia Pacific acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 64. Asia Pacific acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 65. Asia Pacific acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 66. Asia Pacific acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 67. China acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 68. China acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 69. China acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 70. China acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 71. Japan acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 72. Japan acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 73. Japan acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 74. Japan acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 75. India acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 76. India acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 77. India acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 78. India acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 79. Australia acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 80. Australia acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 81. Australia acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 82. Australia acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 83. South Korea acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 84. South Korea acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 85. South Korea acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 86. South Korea acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 87. Thailand acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 88. Thailand acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 89. Thailand acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 90. Thailand acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 91. Latin America acute myeloid leukemia treatment market, by country, 2018 - 2030 (USD Million)
Table 92. Brazil acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 93. Brazil acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 94. Brazil acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 95. Brazil acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 96. Argentina acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 97. Argentina acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 98. Argentina acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 99. Argentina acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 100. Latin America acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 101. Latin America acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 102. Latin America acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 103. Latin America acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 104. Middle East & Africa Acute myeloid leukemia treatment market, by country, 2018 - 2030 (USD Million)
Table 105. Middle East & Africa acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 106. Middle East & Africa acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 107. Middle East & Africa acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 108. Middle East & Africa acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 109. South Africa acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 110. South Africa acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 111. South Africa acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 112. South Africa acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 113. Saudi Arabia acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 114. Saudi Arabia acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 115. Saudi Arabia acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 116. Saudi Arabia acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 117. UAE acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 118. UAE acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 119. UAE acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 120. UAE acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 121. Kuwait acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 122. Kuwait acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 123. Kuwait acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 124. Kuwait acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)

List of Figures
Fig. 1 Acute myeloid leukemia treatment market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Treatment and route of administration outlook (USD Million)
Fig. 10 End use outlook (USD Million)
Fig. 11 Competitive landscape
Fig. 12 Acute myeloid leukemia treatment market dynamics
Fig. 13 Acute myeloid leukemia treatment market: Porter’s five forces analysis
Fig. 14 Acute myeloid leukemia treatment market: PESTLE analysis
Fig. 15 Acute myeloid leukemia treatment market: Disease segment dashboard
Fig. 16 Acute myeloid leukemia treatment market: Disease market share analysis, 2024 & 2030
Fig. 17 Myeloblastic leukemia market, 2018 - 2030 (USD Million)
Fig. 18 Myelomonocytic leukemia market, 2018 - 2030 (USD Million)
Fig. 19 Promyelocytic leukemia market, 2018 - 2030 (USD Million)
Fig. 20 Monocytic leukemia market, 2018 - 2030 (USD Million)
Fig. 21 Other diseases market, 2018 - 2030 (USD Million)
Fig. 22 Acute myeloid leukemia treatment market: Treatment segment dashboard
Fig. 23 Acute myeloid leukemia treatment market: Treatment market share analysis, 2024 & 2030
Fig. 24 Chemotherapy market, 2018 - 2030 (USD Million)
Fig. 25 Anti-metabolites market, 2018 - 2030 (USD Million)
Fig. 26 Alkylating agents market, 2018 - 2030 (USD Million)
Fig. 27 Anthracycline drugs market, 2018 - 2030 (USD Million)
Fig. 28 Others market, 2018 - 2030 (USD Million)
Fig. 29 Targeted therapy market, 2018 - 2030 (USD Million)
Fig. 30 FLT3 inhibitors market, 2018 - 2030 (USD Million)
Fig. 31 Rydapt market, 2018 - 2030 (USD Million)
Fig. 32 Vanflyta market, 2018 - 2030 (USD Million)
Fig. 33 Xospata market, 2018 - 2030 (USD Million)
Fig. 34 IDH inhibitors market, 2018 - 2030 (USD Million)
Fig. 35 Tibsovo market, 2018 - 2030 (USD Million)
Fig. 36 Rezlidhia market, 2018 - 2030 (USD Million)
Fig. 37 Idhifa market, 2018 - 2030 (USD Million)
Fig. 38 Mylotarg market, 2018 - 2030 (USD Million)
Fig. 39 BCL-2 inhibitor market, 2018 - 2030 (USD Million)
Fig. 40 Hedgehog pathway inhibitor market, 2018 - 2030 (USD Million)
Fig. 41 Immunotherapy market, 2018 - 2030 (USD Million)
Fig. 42 Bispecific antibodies market, 2018 - 2030 (USD Million)
Fig. 43 Antibody-drug conjugates market, 2018 - 2030 (USD Million)
Fig. 44 Immune checkpoint inhibitors market, 2018 - 2030 (USD Million)
Fig. 45 Chimeric Antigen Receptor (CAR) T-cell therapy market, 2018 - 2030 (USD Million)
Fig. 46 Other treatments market, 2018 - 2030 (USD Million)
Fig. 47 Acute myeloid leukemia treatment market: Route of administration segment dashboard
Fig. 48 Acute myeloid leukemia treatment market: Route of administration market share analysis, 2024 & 2030
Fig. 49 Parenteral market, 2018 - 2030 (USD Million)
Fig. 50 Oral market, 2018 - 2030 (USD Million)
Fig. 51 Acute myeloid leukemia treatment market: End use segment dashboard
Fig. 52 Acute myeloid leukemia treatment market: End use market share analysis, 2024 & 2030
Fig. 53 Hospitals and clinics market, 2018 - 2030 (USD Million)
Fig. 54 Specialty centers market, 2018 - 2030 (USD Million)
Fig. 55 Homecare setting market, 2018 - 2030 (USD Million)
Fig. 56 Ambulatory care centers market, 2018 - 2030 (USD Million)
Fig. 57 Acute myeloid leukemia treatment market revenue, by region
Fig. 58 Regional marketplace: Key takeaways
Fig. 59 Regional marketplace: Key takeaways
Fig. 60 North America acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 61 U.S. country dynamics
Fig. 62 U.S. acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 63 Canada country dynamics
Fig. 64 Canada acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 65 Mexico country dynamics
Fig. 66 Mexico acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 67 Europe acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 68 UK country dynamics
Fig. 69 UK acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 70 Germany country dynamics
Fig. 71 Germany acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 72 France country dynamics
Fig. 73 France acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 74 Italy country dynamics
Fig. 75 Italy acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 76 Spain country dynamics
Fig. 77 Spain acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 78 Norway country dynamics
Fig. 79 Norway acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 80 Sweden country dynamics
Fig. 81 Sweden acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 82 Denmark country dynamics
Fig. 83 Denmark acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 84 Asia Pacific acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 85 Japan country dynamics
Fig. 86 Japan acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 87 China country dynamics
Fig. 88 China acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 89 India country dynamics
Fig. 90 India acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 91 Australia country dynamics
Fig. 92 Australia acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 93 South Korea country dynamics
Fig. 94 South Korea acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 95 Thailand country dynamics
Fig. 96 Thailand acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 97 Latin America acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 98 Brazil country dynamics
Fig. 99 Brazil acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 100 Argentina country dynamics
Fig. 101 Argentina acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 102 MEA acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 103 South Africa country dynamics
Fig. 104 South Africa acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 105 Saudi Arabia country dynamics
Fig. 106 Saudi Arabia acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 107 UAE country dynamics
Fig. 108 UAE acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 109 Kuwait country dynamics
Fig. 110 Kuwait acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 111 Company categorization
Fig. 112 Company market position analysis
Fig. 113 Strategic framework